1. Home
  2. TARS

as 10-07-2025 3:29pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Founded: 2016 Country:
United States
United States
Employees: N/A City: IRVINE
Market Cap: 1.7B IPO Year: 2020
Target Price: $67.14 AVG Volume (30 days): 737.2K
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.31 EPS Growth: N/A
52 Week Low/High: $32.91 - $69.49 Next Earning Date: 11-12-2025
Revenue: $295,521,000 Revenue Growth: 254.45%
Revenue Growth (this year): 137.28% Revenue Growth (next year): 42.84%

Stock Insider Trading Activity of Tarsus Pharmaceuticals Inc. (TARS)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Azamian Bobak R. TARS President/CEO and Board Chair Sep 24 '25 Sell $55.37 6,000 $332,220.00 812,106
LINK WILLIAM J PHD TARS Director Sep 8 '25 Sell $57.00 27,116 $1,545,612.00 143,332
Azamian Bobak R. TARS President/CEO and Board Chair Aug 11 '25 Sell $50.00 6,000 $300,000.00 812,106

Share on Social Networks: